Progress in the development of prognostic and predictive markers for gastrointestinal malignancies

被引:17
作者
Denlinger C.S. [1 ]
Cohen S.J. [1 ]
机构
[1] Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA
关键词
Overall Survival; Epidermal Growth Factor Receptor; Gemcitabine; Clin Oncol; Cetuximab;
D O I
10.1007/s11864-007-0045-x
中图分类号
学科分类号
摘要
Gastrointestinal cancers remain a significant cause of morbidity and mortality. While increasing therapeutic options have improved outcomes for many patients, they have also complicated treatment decision-making. Unfortunately, most patients with advanced gastrointestinal malignancies die from their disease. Prognostic and predictive markers could improve treatment significantly by identifying patients who may or may not require a given therapy, and determining those most likely to benefit from a therapy. Candidates for such markers include blood antigens and circulating tumor cells, tumor enzyme and gene expression, and pharmacodynamic endpoints. In this review, we summarize reported and ongoing research to define and validate prognostic and predictive markers in gastrointestinal malignancies, with an emphasis on colorectal cancer and brief overview of pancreatic and neuroendocrine tumors. © Current Science Inc. 2008.
引用
收藏
页码:339 / 351
页数:12
相关论文
共 88 条
  • [1] Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J., Cancer statistics, 2007, CA Cancer J Clin, 57, 1, pp. 43-66, (2007)
  • [2] De Gramont A., Boni C., Navarro M., Et al., Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years, J Clin Oncol, 25, 18 SUPPL., (2007)
  • [3] Saltz L.B., Cox J.V., Blanke C., Et al., Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer, N Engl J Med, 343, 13, pp. 905-914, (2000)
  • [4] Burris III H.A., Moore M.J., Andersen J., Et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial, J Clin Oncol, 15, 6, pp. 2403-2413, (1997)
  • [5] Oettle H., Post S., Neuhaus P., Et al., Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial, JAMA, 297, 3, pp. 267-277, (2007)
  • [6] Moore M.J., Goldstein D., Hamm J., Et al., Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 25, 15, pp. 1960-1966, (2007)
  • [7] Sargent D.J., Conley B.A., Allegra C., Collette L., Clinical trial designs for predictive marker validation in cancer treatment trials, J Clin Oncol, 23, 9, pp. 2020-2027, (2005)
  • [8] Wanebo H.J., Rao B., Pinsky C.M., Et al., Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer, N Engl J Med, 299, 9, pp. 448-451, (1978)
  • [9] Wolmark N., Fisher B., Wieand H.S., Et al., The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials, Ann Surg, 199, 4, pp. 375-382, (1984)
  • [10] Park Y.J., Park K.J., Park J.G., Lee K.U., Choe K.J., Kim J.P., Prognostic factors in 2230 Korean colorectal cancer patients: Analysis of consecutively operated cases, World J Surg, 23, 7, pp. 721-726, (1999)